<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421174</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0403</org_study_id>
    <secondary_id>BMT CTN 0403</secondary_id>
    <secondary_id>U01HL069294-05</secondary_id>
    <secondary_id>465</secondary_id>
    <nct_id>NCT00421174</nct_id>
  </id_info>
  <brief_title>Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)</brief_title>
  <official_title>A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation (BMT CTN #0403)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a Phase III, multi-center randomized, double-blind,
      placebo-controlled trial investigating the use of etanercept for the treatment of acute,
      non-infectious pulmonary dysfunction (IPS) occurring after allogeneic hematopoietic cell
      transplantation (HCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Over the last two decades, allogeneic hematopoietic cell transplantation (HCT) has emerged as
      an important treatment for a number of malignant and non-malignant disorders. Unfortunately,
      several complications, including graft-versus-host disease (GVHD) and pulmonary dysfunction,
      limit the utility of this aggressive form of therapy. Infectious and non-infectious lung
      complications occur in 25% to 55% of HCT recipients and account for up to 50% of
      transplant-related mortality. In about half of affected patients, no infectious organisms are
      identified in the lungs. Two major types of non-infectious pulmonary injury are recognized:
      acute idiopathic pneumonia syndrome (IPS) and sub-acute lung injury (obstructive airway
      disease or bronchiolitis obliterans [BrOb] and restrictive lung disease). The current study
      will examine the use of etanercept in patients with IPS.

      DESIGN NARRATIVE:

      Eligible patients will be randomized to receive one of two arms of therapy: (A) etanercept
      plus corticosteroids, or (B) placebo plus corticosteroids. Patients will receive a total of
      eight doses of etanercept (or placebo) over a 4-week period. The initial dose of etanercept
      (or placebo) will be administered intravenously on Day 0, with subsequent doses administered
      subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The
      placebo will be the inert diluent used for the etanercept formulation.

      Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through
      Day 7, with subsequent taper as clinically indicated. Chest radiographs shall be obtained
      weekly through Day 28. Plasma cytokine profiles will be obtained on Days 0, 7, and 28.

      For patients &lt; 30 days post-transplant: If the patient's clinical condition is such that a
      broncho-alveolar lavage (BAL) is deemed &quot;not possible to be performed&quot; by the treating
      physician (or pulmonologist), then the &quot;on study&quot; BAL may be waived. In such circumstances,
      the patient may register and be randomized to study therapy without the BAL being undertaken.

      For patients not on mechanical ventilation: If a BAL is not done, appropriate virology
      studies on a nasal swab (or nasal washing) are required as a minimum procedure to study
      entry.

      For patients on mechanical ventilation: Microbiologic studies of a deep endotracheal aspirate
      are allowed in lieu of a formal bronchoscopy procedure. However, no protocol-specified
      biologic studies (see Section 4.4) will be done on these specimens.

      For patients 31-180 days post-transplant: An &quot;on study&quot; bronchoscopy is required in all
      cases.

      If, at any point following initiation of study drug therapy, previously obtained BAL fluid
      cultures or other BAL fluid analysis become positive for an infectious pathogen, study drug
      therapy shall be discontinued at that point, and not re-instituted. The patient will
      discontinue study drug therapy, but will still be followed for outcome.

      The primary study endpoint is response at Day 28. Patients who discontinue study drug therapy
      for any reason will still be followed for primary and secondary study endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Day 28</time_frame>
    <description>Response will be defined as survival to Day 28 of study, plus discontinuation of all supplemental oxygen support for more than 72 consecutive hours by Day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to Therapy</measure>
    <time_frame>Day 56</time_frame>
    <description>Response will be defined as the ability to survive to Day 56 of study, plus the ability to completely discontinue all supplemental oxygen support for &gt; 72 consecutive hours during this time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of Supplemental Oxygen</measure>
    <time_frame>Day 56</time_frame>
    <description>The &quot;time required to discontinue supplemental oxygen&quot; will be measured in the number of days from study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid Dose</measure>
    <time_frame>Day 14 and 28</time_frame>
    <description>Patients were treated with systemic corticosteroids with methylprednisolone at 2 mg/kg/day on day 0, with taper allowed after day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Year 1</time_frame>
    <description>Percentage of patients that survived after one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infection</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicity</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft-vs-Host-Disease (GVHD)</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse</measure>
    <time_frame>Year 1</time_frame>
    <description>Percentage of patients who experience relapse. Deaths without relapse are considered as a competing risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatologic Reaction</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory Markers of Pulmonary Disease, in Both BAL Fluid and Plasma</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pneumonia</condition>
  <condition>Idiopathic Pneumonia Syndrome</condition>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etanercept plus corticosteroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo plus Corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus corticosteroid</intervention_name>
    <description>Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.
Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Methylprednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients fulfilling the following criteria will be eligible for registration in this study:

          -  Recipient of an allogeneic bone marrow, cord blood, or peripheral blood stem cell
             transplant. There are no restrictions based upon underlying disease, donor source,
             degree of human leukocyte antigen (HLA) match, intensity of the pre-transplant
             conditioning regimen, or the use of a prior donor leukocyte infusion

          -  Evidence of acute lung injury, based upon the presence of bilateral pulmonary
             infiltrates (on chest radiograph) and a supplemental oxygen requirement

          -  No more than 180 days post transplant

        Patients fulfilling the following criteria will be eligible for random assignment in this
        study:

          -  BAL fluid negative for pathogenic microorganisms as assessed by gram stain and fungal
             stain

          -  BAL fluid negative for pathogenic microorganisms, or test result pending, as assessed
             by the following tests:

               1. Acid fast bacilli stain (AFB)

               2. Bacterial culture (a quantitative culture of at least 10(4) CFU/mL is considered
                  positive)

               3. Viral cultures for respiratory pathogens, including Respiratory syncytial virus
                  (RSV), adenovirus, parainfluenza, influenza A and B, and Cytomegalovirus (CMV)

               4. Fungal and mycobacterial cultures

               5. Pneumocystis carinii pneumonia (PCP) assay, by polymerase chain reaction (PCR),
                  direct fluorescent antibody (DFA) stain, or cytology (per institutional
                  guidelines)

        Exclusion Criteria:

          -  Sepsis syndrome or hypotension in which inotropic support (excluding dopamine of no
             more than 5 mcg/kg/minute) is required

          -  Bacteremia within 48 hours prior to study registration

          -  Documented invasive fungal or systemic viral infection (excluding asymptomatic
             viruria) within 14 days prior to study registration

          -  Evidence of CMV infection, based upon an abnormal PCR assay, antigenemia assay, or
             shell vial culture within 14 days of study registration

          -  On mechanical ventilation for more than 48 hours at study registration

          -  Evidence of congestive heart failure by clinical assessment

          -  Participating in other investigational studies (Phase I, II, or III) for the treatment
             of acute GVHD within 7 days of study registration (patients enrolled in BMT CTN 0302
             are ineligible for study entry)

          -  Received etanercept within 14 days prior to study registration

          -  Pregnant or breastfeeding

          -  On more than 2 mg/kg/day of methylprednisolone equivalent for more than 48 hours,
             within 7 days prior to study registration

          -  Known hypersensitivity to etanercept

          -  History of active tuberculosis (TB) infection

          -  History of chronic active hepatitis B or hepatitis C infection

          -  Patients who have undergone a BAL within 72 hours of study registration are ineligible
             if the BAL fluid is known to be positive for pathogenic microorganisms

          -  Patients who have relapsed or have developed progressive disease post-transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Partners Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>https://bethematch.org/</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun;20(6):858-64. doi: 10.1016/j.bbmt.2014.02.026. Epub 2014 Mar 7.</citation>
    <PMID>24607553</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>January 28, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etanercept</keyword>
  <keyword>IPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from September 2007 to August 2011 from 12 different sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etanercept</title>
          <description>Etanercept plus corticosteroids</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo plus Corticosteroids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible due to infection</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etanercept</title>
          <description>Etanercept plus corticosteroids</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo plus Corticosteroids</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" lower_limit="22.9" upper_limit="70.1"/>
                    <measurement group_id="B2" value="46.4" lower_limit="21.8" upper_limit="68.8"/>
                    <measurement group_id="B3" value="46.6" lower_limit="21.8" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Myelogenous Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndrome (MDS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent = 100, good = 70-90, fair = 50-60, poor &lt; 50), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>70 - 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 - 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Conditioning Regimen</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Myeloablative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-myeloablative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient Cytomegalovirus Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Bilirubin</title>
          <description>Serum total bilirubin (mg/dl) at study entry.</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" lower_limit="0.2" upper_limit="18.9"/>
                    <measurement group_id="B2" value="0.9" lower_limit="0.2" upper_limit="10.7"/>
                    <measurement group_id="B3" value="1.0" lower_limit="0.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <description>Serum creatinine (mg/dl) at study entry.</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0.6" upper_limit="2.5"/>
                    <measurement group_id="B2" value="1.4" lower_limit="0.4" upper_limit="2.9"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0.4" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oxygen Support</title>
          <description>Method of supplemental oxygen support at study entry.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nasal cannula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Face mask</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response will be defined as survival to Day 28 of study, plus discontinuation of all supplemental oxygen support for more than 72 consecutive hours by Day 28.</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response will be defined as survival to Day 28 of study, plus discontinuation of all supplemental oxygen support for more than 72 consecutive hours by Day 28.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="35.4" upper_limit="84.8"/>
                    <measurement group_id="O2" value="66.7" lower_limit="41.0" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Therapy</title>
        <description>Response will be defined as the ability to survive to Day 56 of study, plus the ability to completely discontinue all supplemental oxygen support for &gt; 72 consecutive hours during this time period.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Therapy</title>
          <description>Response will be defined as the ability to survive to Day 56 of study, plus the ability to completely discontinue all supplemental oxygen support for &gt; 72 consecutive hours during this time period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="29.9" upper_limit="80.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="26.0" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation of Supplemental Oxygen</title>
        <description>The “time required to discontinue supplemental oxygen” will be measured in the number of days from study entry.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation of Supplemental Oxygen</title>
          <description>The “time required to discontinue supplemental oxygen” will be measured in the number of days from study entry.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="1" upper_limit="36"/>
                    <measurement group_id="O2" value="7" lower_limit="2" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corticosteroid Dose</title>
        <description>Patients were treated with systemic corticosteroids with methylprednisolone at 2 mg/kg/day on day 0, with taper allowed after day 7.</description>
        <time_frame>Day 14 and 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Corticosteroid Dose</title>
          <description>Patients were treated with systemic corticosteroids with methylprednisolone at 2 mg/kg/day on day 0, with taper allowed after day 7.</description>
          <units>mg/kg/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.56" upper_limit="1.92"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.25" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.03" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percentage of patients that survived after one year</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percentage of patients that survived after one year</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="6.5" upper_limit="46.3"/>
                    <measurement group_id="O2" value="16.7" lower_limit="4.1" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Infection</title>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infection</title>
          <units>Infections</units>
          <param>Number</param>
          <units_analyzed>Total number of infections</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bacterial infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Toxicity</title>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Toxicity</title>
          <units>Toxcities</units>
          <param>Number</param>
          <units_analyzed>Total number of toxicities</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of toxicities</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central nervous system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Graft-vs-Host-Disease (GVHD)</title>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Graft-vs-Host-Disease (GVHD)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="11.0" upper_limit="58.7"/>
                    <measurement group_id="O2" value="44.4" lower_limit="21.5" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="7.3" upper_limit="52.4"/>
                    <measurement group_id="O2" value="27.8" lower_limit="9.7" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="1.6" upper_limit="38.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Relapse</title>
        <description>Percentage of patients who experience relapse. Deaths without relapse are considered as a competing risk.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Relapse</title>
          <description>Percentage of patients who experience relapse. Deaths without relapse are considered as a competing risk.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mortality</title>
        <time_frame>Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatologic Reaction</title>
        <time_frame>Day 28</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatologic Reaction</title>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pro-inflammatory Markers of Pulmonary Disease, in Both BAL Fluid and Plasma</title>
        <time_frame>Day 28</time_frame>
        <population>No data collected</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept</title>
            <description>Etanercept plus corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus Corticosteroids</description>
          </group>
        </group_list>
        <measure>
          <title>Pro-inflammatory Markers of Pulmonary Disease, in Both BAL Fluid and Plasma</title>
          <population>No data collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-year post transplant</time_frame>
      <desc>Serious adverse events are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected adverse events are reported here.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etanercept</title>
          <description>Etanercept plus corticosteroids</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo plus Corticosteroids</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, PhD</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>(301) 251-1161 ext 221</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

